- Home
- SNT vs STTK Comparison
SNT vs STTK Comparison
Compare SNT & STTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNT
- STTK
- Stock Information
- Founded
- SNT 1965
- STTK 2016
- Country
- SNT Canada
- STTK United States
- Employees
- SNT N/A
- STTK N/A
- Industry
- SNT Telecommunications Equipment
- STTK Biotechnology: Pharmaceutical Preparations
- Sector
- SNT Telecommunications
- STTK Health Care
- Exchange
- SNT Nasdaq
- STTK Nasdaq
- Market Cap
- SNT 64.6M
- STTK 54.4M
- IPO Year
- SNT 1993
- STTK 2020
- Fundamental
- Price
- SNT $3.45
- STTK $1.16
- Analyst Decision
- SNT
- STTK Hold
- Analyst Count
- SNT 0
- STTK 3
- Target Price
- SNT N/A
- STTK $2.00
- AVG Volume (30 Days)
- SNT 73.4K
- STTK 332.9K
- Earning Date
- SNT 11-12-2024
- STTK 11-14-2024
- Dividend Yield
- SNT N/A
- STTK N/A
- EPS Growth
- SNT N/A
- STTK N/A
- EPS
- SNT 0.06
- STTK N/A
- Revenue
- SNT $34,455,000.00
- STTK $6,435,000.00
- Revenue This Year
- SNT N/A
- STTK $313.04
- Revenue Next Year
- SNT N/A
- STTK N/A
- P/E Ratio
- SNT $54.86
- STTK N/A
- Revenue Growth
- SNT 2.04
- STTK 382.75
- 52 Week Low
- SNT $1.08
- STTK $0.94
- 52 Week High
- SNT $3.35
- STTK $11.76
- Technical
- Relative Strength Index (RSI)
- SNT 71.93
- STTK 44.02
- Support Level
- SNT $2.90
- STTK $1.07
- Resistance Level
- SNT $3.09
- STTK $1.38
- Average True Range (ATR)
- SNT 0.19
- STTK 0.12
- MACD
- SNT 0.00
- STTK 0.01
- Stochastic Oscillator
- SNT 98.16
- STTK 27.88
About SNT Senstar Technologies Ltd.
Senstar Technologies Corp is a provider of comprehensive physical, video, and access control security products and solutions. Its perimeter intrusion detection systems (including fence sensors, buried sensors, and above-ground sensors), intelligent video management, video analytics, and access control offer a comprehensive suite of integrated solutions that reduce complexity, improve performance, and unify support.
About STTK Shattuck Labs Inc.
Shattuck Labs Inc is a clinical-stage biotechnology company pioneering the development of dual-sided fusion proteins as an entirely new class of biologic medicine. Its product candidate, SL-172154, has been rationally designed to simultaneously inhibit the CD47/SIRPa checkpoint interaction to restore an anti-tumor immune response and to activate the CD40 costimulatory receptor to bolster an immune response. Its product candidate, SL-279252, which is being developed in collaboration with Takeda Pharmaceuticals, or Takeda, has been rationally designed to simultaneously inhibit the PD-1/PD-L1 interaction and activate the OX40 receptor.